Watch CNBC's full interview with Eli Lilly CEO David Ricks following Q3 earnings

Eli Lilly CEO David Ricks joins 'Squawk Box' to react to the company's latest quarterly earnings, which missed Wall Street's estimates. Ricks also provides an update into the company's highly watched Alzheimer's drug donanemab and provides an outlook for Lilly's Covid-19 antibodies.